Iksuda receives US FDA IND clearance for IKS04

Source Summary

NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IKS04, a CA242-directed ADC, enabling assessment in a Phase 1 trial in patients with gastrointestinal (GI) cancers. CA242 is a tumour-specific glycotope which is strongly expressed in a variety of GI cancers including the majority of color